No Data
[New Stock IPO] Beijing Tongrentang Medical Care Investment Co., Ltd. has submitted a listing application to the Main Board of the Hong Kong Stock Exchange.
Jingwu Finance News | According to the Hong Kong Stock Exchange's disclosure on December 31, Beijing Tongrentang Medical and Nursing Investment Co., Ltd. submitted a listing application to the Main Board of the Hong Kong Stock Exchange, with China International Capital Corporation as the exclusive sponsor. The company is a leading Traditional Chinese Medicine medical group, consisting of its own and managed medical institutions at three levels: chain hospitals, grassroots chain medical institutions (including outpatient departments, clinics, and Community health institutions, all independent medical institutions in China that Hold various types of licenses or certificates to operate), and Internet Plus-Related hospitals. Combining "medicine" and "nursing," the company provides modern and customized Traditional Chinese Medicine Medical Services, covering all scenarios with standardized management, utilizing its advantageous specialties.
Beijing Tongrentang (600085.SH) and its holding subsidiaries plan to lease properties.
On December 30, Gelonghui reported that Beijing Tongrentang (600085.SH) announced that in 2025, the company and its controlling subsidiary, Peking Tongrentang Commercial Investment Group Co., Ltd. (referred to as Tongrentang Commercial), plan to lease properties from China Peking Tongrentang (Group) Co., Ltd. (including its subsidiaries, excluding the scope of the company's consolidated financial statements, referred to as Tongrentang Group) to meet production, operation, and daily office needs, with an annual rent totaling no more than 20 million yuan; the company plans to lease properties to Tongrentang Group to enhance the operational capacity of some idle properties, with an annual rent totaling no more than 5 million yuan.
Beijing Tongrentang (600085.SH): Plans to sign a framework agreement for brand licensing with related parties.
On December 30, GELONGHUI reported that TONG REN TANG (600085.SH) announced that the "TONG REN TANG" trademark and name are owned by TONG REN TANG Group. In order to fully protect the interests of all parties, reasonably safeguard the value of state-owned Assets, and ensure the continuous and stable Operation of the company and its holding subsidiary TONG REN TANG Technology, as well as TONG REN TANG Commercial, the company and its holding subsidiaries intend to sign a "Brand License Framework Agreement" with TONG REN TANG Group, with a term of three years, agreeing that the company, TONG REN TANG Technology, TONG REN TANG Commercial, and affiliated enterprises using the "TONG REN TANG" brand (hereinafter referred to as member units) will pay TONG REN TANG Group the fees related to the use of the "TONG REN TANG" brand.
TONGRENTANGCM (03613.HK) has entered into a technical service contract with TONG REN TANG.
On December 20, Gelonghui reported that TONGRENTANGCM (03613.HK) announced that on December 20, 2024, the company entered into a technical service contract with TONG REN TANG. Accordingly, the company entrusted TONG REN TANG with the process and technical research on important Traditional Chinese Medicine raw materials. The company shall pay TONG REN TANG a total of 5 million Hong Kong dollars in installments for the technical services. The related raw materials are an important part of the group's production of Traditional Chinese Medicine and products, playing a significant role in the quality of the production process. Considering TONG REN TANG's capabilities and expertise in Traditional Chinese Medicine manufacturing, the Director believes that the technical service contract and the Trade involved will be beneficial.
HAITONG INT'L: Bullish on the bottom reversal of the Traditional Chinese Medicine Industry, with the State-owned Enterprise Reform and mergers and acquisitions resonating in development.
As aging continues to intensify, the demand in the Silver economy and chronic disease medication-related fields is viewed as Bullish.
beijing tongrentang channel research: the high-end series has started to layout, there are still "gaps" in the out-of-hospital channels, and mergers and acquisitions have taken root in the in-hospital market | company research
① This Friday, the chairman of beijing tongrentang, Di Shubing, officially assumes the role of general manager of beijing tongrentang Group. ② The high-end imperial medicine series is primarily sold in beijing tongrentang pharmacies and remains hard to find in some city chain pharmacies. The company stated that the overall sales situation is in line with expectations. ③ beijing tongrentang Commercial Company acquired 51% of Honghui Medical for 0.105 billion, exploring the medical market, but there are still gaps in the outpatient medium and large chain market.
No Data